Search research articles
Contact Us
Filters
Showing results (51-60 of 110) with videos related to
Page
of 11
Sort By:
Investigational New Drugs
|
January 1, 1984
Menogaril: a new anthracycline agent entering clinical trials
J P McGovren, K G Nelson, M Lassus, et al.
Traffic (Copenhagen, Denmark)
|
April 28, 2007
Cholesterol-sensitive Cdc42 activation regulates actin polymerization for endocytosis via the GEEC pathway
Rahul Chadda, Mark T Howes, Sarah J Plowman, et al.
Biochemical Pharmacology
|
January 12, 1996
Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin
E Hamel, C M Lin, J Plowman, et al.
Molecular Biology of the Cell
|
September 12, 2008
Activation of the MAPK module from different spatial locations generates distinct system outputs
Kerry Inder, Angus Harding, Sarah J Plowman, et al.
International Journal of Food Microbiology
|
September 5, 2008
Modelling the growth of Clostridium perfringens during the cooling of bulk meat
Y Le Marc, J Plowman, C F Aldus, et al.
Investigational New Drugs
|
January 1, 1983
Spiromustine: a new agent entering clinical trials
D D Shoemaker, P J O'Dwyer, S Marsoni, et al.
Cancer Chemotherapy and Pharmacology
|
January 11, 1992
Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice
W R Waud, J Plowman, S D Harrison, et al.
Cancer Research
|
August 15, 2008
K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3
Ruby Shalom-Feuerstein, Sarah J Plowman, Barak Rotblat, et al.
Investigational New Drugs
|
December 1, 1988
Pyrazole: preclinical reassessment
P J O'Dwyer, S A King, J Plowman, et al.
Cancer Treatment Reports
|
May 1, 1986
Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice
J Plowman, V L Narayanan, D Dykes, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 110) with videos related to
Sort By:
Page
of 11
Investigational New Drugs
|
January 1, 1984
Menogaril: a new anthracycline agent entering clinical trials
J P McGovren, K G Nelson, M Lassus, et al.
Traffic (Copenhagen, Denmark)
|
April 28, 2007
Cholesterol-sensitive Cdc42 activation regulates actin polymerization for endocytosis via the GEEC pathway
Rahul Chadda, Mark T Howes, Sarah J Plowman, et al.
Biochemical Pharmacology
|
January 12, 1996
Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin
E Hamel, C M Lin, J Plowman, et al.
Molecular Biology of the Cell
|
September 12, 2008
Activation of the MAPK module from different spatial locations generates distinct system outputs
Kerry Inder, Angus Harding, Sarah J Plowman, et al.
International Journal of Food Microbiology
|
September 5, 2008
Modelling the growth of Clostridium perfringens during the cooling of bulk meat
Y Le Marc, J Plowman, C F Aldus, et al.
Investigational New Drugs
|
January 1, 1983
Spiromustine: a new agent entering clinical trials
D D Shoemaker, P J O'Dwyer, S Marsoni, et al.
Cancer Chemotherapy and Pharmacology
|
January 11, 1992
Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice
W R Waud, J Plowman, S D Harrison, et al.
Cancer Research
|
August 15, 2008
K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3
Ruby Shalom-Feuerstein, Sarah J Plowman, Barak Rotblat, et al.
Investigational New Drugs
|
December 1, 1988
Pyrazole: preclinical reassessment
P J O'Dwyer, S A King, J Plowman, et al.
Cancer Treatment Reports
|
May 1, 1986
Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice
J Plowman, V L Narayanan, D Dykes, et al.
Page
of 11